The inhibition of phospholipase (PL) and cholesterol esterase (CE) to prevent the absorption of triglycerides and cholesterol esters is a therapy strategy for hyperlipidemia and other lipid metabolism disorders [4]. This evidence concerns the gene PNLIP and hyperlipidemia.